PromiseBio provides a cloud-based AI platform for broad-range epiproteomic analyses using standard mass-spectrometry data. This platform uncovers hidden insights into Post Translational Modifications (PTMs) that regulate protein activity, crucial for understanding autoimmune diseases. The resulting explainable, biologically-relevant data supports precision medicine applications like treatment selection and biomarker discovery.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
APFounders
Product
Problem
Current methods for predicting treatment response and stratifying patients with autoimmune diseases often lack the scalability and accuracy needed for personalized medicine. Traditional proteomic analyses may overlook critical post-translational modifications (PTMs) that regulate protein activity and function, hindering a comprehensive understanding of disease mechanisms.
Solution
PromiseBio offers a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data to uncover hidden insights into autoimmune diseases. By studying post-translational modifications (PTMs), the platform provides a comprehensive view of disease mechanisms and captures the regulated proteome. The platform leverages explainable AI and clinically-oriented algorithms to provide high-impact recommendations for treatment selection, early assessment of response, and disease monitoring. PromiseBio's approach enables true scalability in response prediction and patient stratification, facilitating precision medicine for autoimmune diseases.
Target Audience
PromiseBio targets pharmaceutical companies seeking to boost drug development through biomarker discovery and patient selection, as well as clinicians aiming to enable precision medicine through improved treatment selection and disease monitoring for patients with autoimmune diseases.
Features
- Cloud-based AI platform for epiproteomic analyses
- Unbiased approach exploring a broad range of the PTM landscape
- Integration of chemical knowledge, statistics, and advanced algorithms
- Explainable AI and clinically-oriented algorithms for high-impact recommendations
- Leveraging of standard mass-spectrometry data without chemical enrichment
- Identification of biomarkers for autoimmune diseases
- Prediction of treatment response and patient stratification